Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - POINT Biopharma Global Inc. | tm2024892d1_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 16, 2020 (July 10, 2020)
THERAPEUTICS ACQUISITION CORP.
(Exact name of registrant as specified in its charter)
|
Delaware (State or other jurisdiction of incorporation) |
001-39373 (Commission File Number) |
85-0800493 (I.R.S. Employer Identification No.) |
200 Berkeley Street (Address of principal executive offices) |
02116 (Zip Code) |
(617) 778.2500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbols |
Name of each exchange on which registered | ||
|
Class A common stock, par value $0.0001 per share |
TXAC | The Nasdaq Capital Market |
| x | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| ¨ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
| Item 8.01 | Other Events |
On July 10, 2020, Therapeutics Acquisition Corp. (the “Company”) consummated its initial public offering (“IPO”) of 13,570,000 shares of Class A common stock (the "Class A Common Stock"), including the issuance of 1,770,000 shares as a result of the underwriters' exercise in full of their over-allotment option. The Class A Common Stock was sold at a price of $10.00 per share, generating gross proceeds to the Company of $135,700,000.
On July 10, 2020, substantially concurrent with the consummation of the IPO, the Company completed the private sale (the “Private Placement”) of an aggregate of 471,400 shares of Class A common Stock (the “Private Placement Shares”) to Therapeutics Acquisition Holdings LLC at a purchase price of $10.00 per Private Placement Share, generating gross proceeds to the Company of $4,714,000.
An audited balance sheet as of July 10, 2020 reflecting receipt of the proceeds upon consummation of the IPO and the Private Placement has been issued by the Company and is included as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Audited Balance Sheet as of July 10, 2020. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Therapeutics Acquisition Corp. | ||
| Date: July 16, 2020 | By: | /s/ Matthew Hammond |
| Name: | Matthew Hammond | |
| Title: | Chief Financial Officer | |